Referencing for people who value simplicity, privacy, and speed.Get Citationsy
← Back to Search
Positive Association Between Circulating 25-hydroxyvitamin D Levels And Prostate Cancer Risk: New Findings From An Updated Meta-analysis
Yong-hua Xu, Xiaoping Shao, Y. Yao, L. Xu, Liang Chang, Zhuojuan Jiang, Zhaofen Lin
Published 2014 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
PurposeTo investigate and clarify the relationship between circulating 25-hydroxyvitamin D level and prostate cancer risk.MethodsWe conducted the meta-analysis to better evaluate the association. Terms “25-Hydroxyvitamin D”/“vitamin D” and “prostate cancer” were used for literature search.ResultsWe identified 21 relevant publications from databases of PubMed and MEDLINE and included 11,941 cases and 13,870 controls in the meta-analysis. Overall studies revealed a significant 17 % elevated risk of prostate cancer for individuals with higher level of 25-hydroxyvitamin D (OR = 1.17, 95 % CI = 1.05–1.30, P = 0.004), and no publication bias was found in the calculations (P = 0.629). Subgroup analysis confirmed the association from nested case–control study group, studies from USA group and studies using serum samples group (nested case–control studies: OR = 1.17, 95 % CI = 1.08–1.27, P < 0.001; USA: OR = 1.15, 95 % CI = 1.03–1.29, P = 0.017; serum: OR = 1.20, 95 % CI = 1.01–1.42, P = 0.042); moreover, sensitivity tests also indicated significant results in studies from Europe and studies conducting with plasma samples after exclusion of some influential single study from the analysis, respectively (Europe: OR = 1.21, 95 % CI = 1.04–1.40, P = 0.014; plasma: OR = 1.13, 95 % CI = 1.00–1.27, P = 0.05).ConclusionsOur meta-analysis, for the first time, suggested significant positive relationship between high level of 25-hydroxyvitamin D and increased risk of prostate cancer, reminding us that more concern should be taken into account during assessing the effect of 25-hydroxyvitamin D.
This paper references
Lack of Association between Serum Levels of 25-Hydroxyvitamin D and the Subsequent Risk of Prostate Cancer in Finnish Men
J. Faupel-Badger (2007)
Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D, and prostate cancer risk
B. Mikhak (2007)
22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer.
K. Nakagawa (2005)
Vitamin Drelated genes , serum vitamin D concentrations and prostate cancer risk
J ahn (2009)
Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case–control study
Johan Brändstedt (2012)
Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer
P. Tuohimaa (2007)
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
Associations of circulating 25‐hydroxyvitamin D with prostate cancer diagnosis, stage and grade
R. Gilbert (2012)
Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer
E. Jacobs (2004)
The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis.
A. Pittas (2007)
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.
J. Ahn (2009)
The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates.
W. Grant (2006)
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis
R. Gilbert (2010)
Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis.
L. Yin (2013)
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
M. Ahonen (2004)
Effect of Vitamin D on falls: a meta-analysis.
H. Bischoff-Ferrari (2004)
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries
P. Tuohimaa (2004)
Estimation of total usual calcium and vitamin D intakes in the United States.
R. Bailey (2010)
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
A. Nomura (2004)
A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer
H. Li (2007)
Prostate lC, Ovarian Cancer screening trial Project t (2008) serum vitamin D concentration and prostate cancer risk: a nested casecontrol study
J ahn (2008)
A Systematic Review and Meta-analysis
P. Chan (2010)
risk and prediagnostic serum 25hydroxyvitamin D levels ( Finland )
tenkanen l (2000)
Serum Vitamin D and Risk of Prostate Cancer in a Case-Control Analysis Nested Within the European Prospective Investigation into Cancer and Nutrition (EPIC)
R. Travis (2009)
Risk of Prostate Cancer in a Randomized Clinical Trial of Calcium Supplementation
J. Baron (2005)
Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men
C. Barnett (2010)
25-Hydroxyvitamin D, IGF-1, and Metabolic Syndrome at 45 Years of Age
E. Hyppönen (2008)
Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer
E. Platz (2004)
Meta-analysis in clinical trials.
R. Dersimonian (1986)
Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study.
P. Pazdiora (2011)
Plasma 1 , 25dihydroxyand 25hydroxyvitamin D and subsequent risk of prostate cancer
Porojnicu aC (2007)
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.
J. Ma (1998)
( hawaii , United states )
JM Ordonez-Mena (2013)
25-hydroxyvitamin D, IgF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 57(2):298–305
e hypponen (2008)
A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers.
R. Stolzenberg-Solomon (2006)
25-hydroxyvitamin D, insulin-like growth factor 1 and metabolic syndrome at age 45y: a cross-sectional study in the 1958 British birth cohort
E. Hyppönen (2007)
Folate: a magic bullet or a double edged sword for colorectal cancer prevention?
Y. Kim (2006)
thomas Mg, Binderup l, hague a (2000) apoptosis is induced by the active metabolite of vitamin
Diaz gD (2000)
Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study.
I. Shui (2012)
Key tJ (2009) serum vitamin D and risk of prostate cancer in a case-control analysis nested within the european Prospective
MV arguelles (2009)
H. Pols (2007)
Cancer statistics, 2014
R. Siegel (2014)
Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
G. Díaz (2000)
Vitamins and Prostate Cancer Risk
K. V. Donkena (2010)
The effect of vitamin D on falls: a meta-analysis
Z. Qiu (2013)
A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland)
P. Mitrou (2007)
Meta‐analysis of observational studies of serum 25‐hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma
S. Gandini (2011)
Vitamin D and cardiovascular outcomes: a systematic review and metaanalysis
MB elamin (2011)
Serum 25-Hydroxy Vitamin D and Prostate Cancer Risk in a Large Nested Case–Control Study
D. Albanes (2011)
Serum 25-Hydroxyvitamin D and Cancer Risk in Older Adults: Results from a Large German Prospective Cohort Study
J. Ordóñez-Mena (2013)
Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies.
H. Meyer (2013)
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate
J Ma (1998)
The epidemiology of vitamin D and cancer incidence and mortality: A review (United States)
E. Giovannucci (2004)
sJ, schatzkin a, hayes RB, Prostate lC, Ovarian trial Project t (2009) Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis
J ahn (2009)
Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms
S. A. Lamprecht (2003)
Folic acid fortification: a double-edged sword
M. Lucock (2009)
Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer.
D. Albanes (2009)
Metaanalysis of longitudinal studies: serum vitamin D and prostate cancer risk
Yin l (2009)
Serum vitamin D concentration and prostate cancer risk: a nested case-control study.
J. Ahn (2008)
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
P. Stattin (2000)
Vitamins and prostate cancer risk. Molecules 15(3):1762–1783
KV Donkena (2010)
Understanding prostate cancer
E. Siddiqui (2004)
Operating characteristics of a rank correlation test for publication bias.
C. Begg (1994)
Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort.
S. Park (2010)
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
M. Braun (2004)
Serum 25-hydroxyvitamin D and prevention of breast cancer: pooled analysis.
S. Mohr (2011)
Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis.
M. Elamin (2011)
Statistical aspects of the analysis of data from retrospective studies of disease.
N. Mantel (1959)
A U-shaped relationship between plasma folate and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition.
S. Chuang (2011)
Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials
H. Bischoff-Ferrari (2009)
Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?
A. Porojnicu (2007)
Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies
B. Schöttker (2013)
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
June M. Chan (1998)
Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk.
L. Yin (2009)
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
Kristin K. Deeb (2007)
This paper is referenced by
Metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.
Shakira M. Nelson (2016)
Vitamin D, PTH, and calcium in relation to survival following prostate cancer
Johan Brändstedt (2016)
The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: A review of the epidemiology, clinical trials, and mechanisms
M. Moukayed (2017)
Vitamin D supplementation for prevention of cancer: The D2d cancer outcomes (D2dCA) study.
R. Chatterjee (2019)
A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk
M. Deschasaux (2015)
Association between serum 25‐hydroxyvitamin D and serum sex steroid hormones among men in NHANES
G. Anic (2016)
Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men
T. Layne (2017)
Association between metabolic syndrome, hepatic steatosis, and testosterone deficiency: evidences from studies with men and rodents.
D. A. M. Hermoso (2020)
Dietary Carcinogens and DNA Adducts in Prostate Cancer.
Medjda Bellamri (2019)
Circulating vitamin D level and mortality in prostate cancer patients: a dose–response meta-analysis
Zhen-yu Song (2018)
Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?
M. Marian (2017)
To Study the Association of Vitamin D and Inflammation in Prostate Cancer Patients of Northern India
K. Taneja (2020)
Prostate cancer risk factors in black and white men in the NIH-AARP Diet and Health Study
T. Layne (2018)
Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival
S. Weinstein (2018)
Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark
F. J. Vojdeman (2019)
The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials.
Simin Shahvazi (2019)
Lower serum 25-hydroxyvitamin D is associated with colorectal and breast cancer, but not overall cancer risk: a 20-year cohort study.
K. Zhu (2019)
Do studies reporting ‘U’-shaped serum 25-hydroxyvitamin D–health outcome relationships reflect adverse effects?
W. Grant (2016)
The effect of vitamin D on women’s reproductive health
M. Bakleicheva (2018)
REPRODUCTIVE HEALTH AND CARDIOMETABOLIC RISK
V. Chulkov (2018)
Association of Vitamin D With Prostate Carcinoma: A Single Institutional Observational Study
S. K. Choubey (2017)
10 Prostate Cancer
M. Bratton (2017)
Effect of serum 25-hydroxyvitamin D level on lung, breast, colorectal and prostate cancers: a nested case-control study.
A. Acikgoz (2020)
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.
S. Christakos (2016)
Vitamin D Status and Cancer Incidence, Survival, and Mortality.
Hanseul Kim (2020)
Disparities in Head and Neck Cancer: A Case for Chemoprevention with Vitamin D
Mirela Ibrahimovic (2020)
Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l’ostéoporose induite par la castration dans le cancer de la prostate
K. Briot (2019)
Skeletal and Extraskeletal Benefits of Vitamin D
E. Casado (2017)
Roles of Solar UVB and Vitamin D in Reducing Cancer Risk and Increasing Survival.
W. Grant (2016)
Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions
R. Bouillon (2018)
Building a Prostate Cancer Lifestyle Medicine Program
Zach Dovey (2020)
French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
K. Briot (2019)See more